Bio-Rad [BIO.B] vs Penumbra [PEN] Detailed Stock Comparison
Bio-Rad
NYSE
Loading...
Penumbra
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Bio-Rad wins in 11 metrics, Penumbra wins in 7 metrics, with 0 ties. Bio-Rad appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bio-Rad | Penumbra | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 22.30 | 67.16 | Bio-Rad |
| Price-to-Book Ratio | 0.94 | 7.63 | Bio-Rad |
| Debt-to-Equity Ratio | 19.73 | 17.04 | Penumbra |
| PEG Ratio | N/A | -0.39 | N/A |
| EV/EBITDA | 16.38 | 54.69 | Bio-Rad |
| Profit Margin (TTM) | 12.50% | 11.54% | Bio-Rad |
| Operating Margin (TTM) | 12.19% | 12.03% | Bio-Rad |
| EBITDA Margin (TTM) | 12.19% | 12.03% | Bio-Rad |
| Return on Equity | 4.59% | 12.03% | Penumbra |
| Return on Assets (TTM) | 1.59% | 6.20% | Penumbra |
| Free Cash Flow (TTM) | $266.20M | $147.30M | Bio-Rad |
| 1-Year Return | -24.40% | 25.99% | Penumbra |
| Price-to-Sales Ratio (TTM) | 2.84 | 7.71 | Bio-Rad |
| Enterprise Value | $6.72B | $9.67B | Penumbra |
| EV/Revenue Ratio | 2.63 | 7.55 | Bio-Rad |
| Gross Profit Margin (TTM) | 52.99% | 65.99% | Penumbra |
| Revenue per Share (TTM) | $92 | $33 | Bio-Rad |
| Earnings per Share (Diluted) | $11.08 | $3.77 | Bio-Rad |
| Beta (Stock Volatility) | 0.91 | 0.40 | Penumbra |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Bio-Rad vs Penumbra Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bio-Rad | 0.00% | 0.00% | -4.15% | -1.21% | -20.83% | -24.12% |
| Penumbra | 5.32% | 4.63% | 14.17% | -0.75% | -7.98% | 10.31% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bio-Rad | -24.40% | -52.39% | -52.46% | 82.57% | 194.74% | 348.37% |
| Penumbra | 25.99% | 59.61% | 19.82% | 541.02% | 541.02% | 541.02% |
Performance & Financial Health Analysis: Bio-Rad vs Penumbra
| Metric | BIO.B | PEN |
|---|---|---|
| Market Information | ||
| Market Cap | $7.26B | $9.87B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 2 | 333,680 |
| 90 Day Avg. Volume | 11 | 478,483 |
| Last Close | $247.05 | $264.74 |
| 52 Week Range | $225.29 - $359.22 | $184.80 - $310.00 |
| % from 52W High | -31.23% | -14.60% |
| All-Time High | $818.60 (Sep 06, 2021) | $348.67 (Jun 26, 2023) |
| % from All-Time High | -69.82% | -24.07% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | 0.13% |
| Quarterly Earnings Growth | 0.02% | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.12% |
| Operating Margin (TTM) | 0.12% | 0.12% |
| Return on Equity (TTM) | 0.05% | 0.12% |
| Debt to Equity (MRQ) | 19.73 | 17.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $263.42 | $33.20 |
| Cash per Share (MRQ) | $50.76 | $10.89 |
| Operating Cash Flow (TTM) | $534.20M | $201.49M |
| Levered Free Cash Flow (TTM) | $223.40M | $97.77M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Bio-Rad vs Penumbra
| Metric | BIO.B | PEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 22.30 | 67.16 |
| Forward P/E | N/A | 66.98 |
| PEG Ratio | N/A | -0.39 |
| Price to Sales (TTM) | 2.84 | 7.71 |
| Price to Book (MRQ) | 0.94 | 7.63 |
| Market Capitalization | ||
| Market Capitalization | $7.26B | $9.87B |
| Enterprise Value | $6.72B | $9.67B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.63 | 7.55 |
| Enterprise to EBITDA | 16.38 | 54.69 |
| Risk & Other Metrics | ||
| Beta | 0.91 | 0.40 |
| Book Value per Share (MRQ) | $263.42 | $33.20 |
Financial Statements Comparison: Bio-Rad vs Penumbra
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BIO.B | PEN |
|---|---|---|
| Revenue/Sales | $585.40M | $324.14M |
| Cost of Goods Sold | $279.40M | $108.26M |
| Gross Profit | $306.00M | $215.88M |
| Research & Development | $73.50M | $22.08M |
| Operating Income (EBIT) | $23.70M | $40.35M |
| EBITDA | $98.50M | $49.20M |
| Pre-Tax Income | $83.40M | $43.86M |
| Income Tax | $19.40M | $4.64M |
| Net Income (Profit) | $64.00M | $39.22M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BIO.B | PEN |
|---|---|---|
| Cash & Equivalents | $521.40M | $376.05M |
| Total Current Assets | $3.04B | $999.71M |
| Total Current Liabilities | $506.60M | $158.63M |
| Long-Term Debt | $1.33B | $205.85M |
| Total Shareholders Equity | $6.68B | $1.21B |
| Retained Earnings | $7.48B | $99.23M |
| Property, Plant & Equipment | $681.70M | $274.92M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BIO.B | PEN |
|---|---|---|
| Operating Cash Flow | $156.00M | $46.01M |
| Capital Expenditures | $-34.40M | $-13.47M |
| Free Cash Flow | $95.50M | $35.50M |
| Debt Repayment | $-100,000 | $-613,000 |
| Common Stock Repurchase | $-101.90M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BIO.B | PEN |
|---|---|---|
| Shares Short | 102 | 1.52M |
| Short Ratio | N/A | 3.07 |
| Short % of Float | 0.00% | 0.05% |
| Average Daily Volume (10 Day) | 2 | 333,680 |
| Average Daily Volume (90 Day) | 11 | 478,483 |
| Shares Outstanding | 28.01M | 38.49M |
| Float Shares | 18.51M | 37.83M |
| % Held by Insiders | 0.98% | 0.04% |
| % Held by Institutions | 0.00% | 0.94% |
Dividend Analysis & Yield Comparison: Bio-Rad vs Penumbra
| Metric | BIO.B | PEN |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |